May 29, 2020 / 2:12 PM / a month ago

BRIEF-Heat Biologics Presents Positive Survival Benefit For Hs-110 In Combination With Nivolumab In Phase 2 Lung Cancer Trial At 2020 Asco Annual Meeting

May 29 (Reuters) - Heat Biologics Inc:

* HEAT BIOLOGICS PRESENTS POSITIVE SURVIVAL BENEFIT FOR HS-110 IN COMBINATION WITH NIVOLUMAB IN PHASE 2 LUNG CANCER TRIAL AT 2020 ASCO ANNUAL MEETING

* HEAT BIOLOGICS - DATA SHOWED SIGNIFICANT SURVIVAL BENEFIT OBSERVED IN COHORT OF PREVIOUSLY TREATED, CPI NAÏVE PATIENTS WITH ADVANCED NSCLC

* HEAT BIOLOGICS - STATISTICALLY SIGNIFICANT SURVIVAL BENEFIT WITH MOS OF 42.1 MONTHS WAS OBSERVED IN PATIENTS WITH INJECTION SITE REACTION

* HEAT BIOLOGICS - PLANNING AN END-OF-PHASE 2 MEETING WITH FDA TO DISCUSS REGISTRATION TRIAL DESIGN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below